Wan Ismail Faisham1, Arman Zaharil Mat Saad2, Laith N Alsaigh1, Mat Z Nor Azman1, Musa Kamarul Imran3, Biswa M Biswal4, Venkata Mk Bhavaraju4, Md Salleh Salzihan5, Jaafar Hasnan5, Aziz M Ezane6, Nasir Ariffin7, Mohamad Norsarwany7, Mohamad G Ziyadi8, Wan Sulaiman Wan Azman2, Ahmad Sukari Halim2, Wan Zulmi1. 1. Department of Orthopaedics, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia. 2. Reconstructive Sciences Unit, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia. 3. Department of Community Medicine, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia. 4. Department of Radiation Therapy and Oncology, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia. 5. Department of Pathology, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia. 6. Department of Radiology, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia. 7. Department of Pediatric (Oncology), Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia. 8. Cardiothoracic Unit, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian, Kelantan, Malaysia.
Abstract
AIM: Osteosarcoma is a highly malignant primary bone tumor. The study aim to evaluate the prognostic factors influencing the survival rate in our center. METHODS: This was a retrospective cohort study of all patients treated between January 2005 and December 2010. RESULTS: We included 163 patients with an age range of 6-59 years (median = 19). The median follow-up was 47 months (range 36-84). The overall survival in patients who completed chemotherapy and surgery (n = 117) was 72% at 2 years and 44% at 5 years. Histologically, 99 (85%) had osteoblastic, 6 (5%) had chondroblastic and 3 (2.5%) had telangiectatic osteosarcoma. Limb salvage surgery was performed in 80 (49%) and 41 (25%) underwent amputation. However, 46 patients (28%) underwent no surgical intervention and incomplete chemotherapy. In total, 38/79 patients had a good chemotherapy response. There was a significantly better survival rate for limb salvage versus amputation. Independent prognostic factors for survival are compliance to treatment and presence of lung metastasis. CONCLUSION: The overall survival of osteosarcoma patients was influenced by the presence of pulmonary metastases and compliance to treatment. Histological subtype, different chemotherapy regimens and histological necrosis after chemotherapy did not significantly influence survival. The patients who did not complete treatment had significantly poorer survival.
AIM: Osteosarcoma is a highly malignant primary bone tumor. The study aim to evaluate the prognostic factors influencing the survival rate in our center. METHODS: This was a retrospective cohort study of all patients treated between January 2005 and December 2010. RESULTS: We included 163 patients with an age range of 6-59 years (median = 19). The median follow-up was 47 months (range 36-84). The overall survival in patients who completed chemotherapy and surgery (n = 117) was 72% at 2 years and 44% at 5 years. Histologically, 99 (85%) had osteoblastic, 6 (5%) had chondroblastic and 3 (2.5%) had telangiectatic osteosarcoma. Limb salvage surgery was performed in 80 (49%) and 41 (25%) underwent amputation. However, 46 patients (28%) underwent no surgical intervention and incomplete chemotherapy. In total, 38/79 patients had a good chemotherapy response. There was a significantly better survival rate for limb salvage versus amputation. Independent prognostic factors for survival are compliance to treatment and presence of lung metastasis. CONCLUSION: The overall survival of osteosarcomapatients was influenced by the presence of pulmonary metastases and compliance to treatment. Histological subtype, different chemotherapy regimens and histological necrosis after chemotherapy did not significantly influence survival. The patients who did not complete treatment had significantly poorer survival.
Authors: Adriene Pavek; Christopher Nartker; Maamoon Saleh; Matthew Kirkham; Sana Khajeh Pour; Ali Aghazadeh-Habashi; Jared J Barrott Journal: Biomedicines Date: 2021-05-14